Company Overview - Yinos Biotech Co., Ltd. is located in the China (Shanghai) Pilot Free Trade Zone and was established on May 12, 2010. The company is set to be listed on September 3, 2024. Its main business involves providing comprehensive research and development services (CRO) focused on non-clinical research services in the biopharmaceutical sector [1] - The revenue composition of Yinos is as follows: non-clinical services account for 95.42%, clinical services for 4.11%, and other services for 0.47% [1] Stock Performance - On September 1, Yinos shares increased by 5.1%, reaching a price of 40.98 CNY per share, with a trading volume of 30.95 million CNY and a turnover rate of 2.75%. The total market capitalization is 5.777 billion CNY [1] Shareholder Information - Among the top ten circulating shareholders of Yinos, one fund from Harvest Fund Management, the Harvest Medical Health Stock A (005303), entered the top ten in the second quarter, holding 344,300 shares, which represents 1.22% of the circulating shares. The estimated floating profit for today is approximately 685,200 CNY [2] - The Harvest Medical Health Stock A fund was established on December 4, 2017, with a current size of 786 million CNY. Year-to-date returns are 42.3%, ranking 534 out of 4222 in its category. Over the past year, returns are 50.75%, ranking 1765 out of 3779, and since inception, the fund has achieved a return of 93.9% [2] Fund Management - The fund manager for Harvest Medical Health Stock A is Sun Xiaohui, who has been in position for 144 days, with a total fund size of 985 million CNY. The best return during his tenure is 37.64%, while the worst is 37.22% [3] - The other fund manager, Hao Miao, has been in position for 6 years and 230 days, managing a total fund size of 3.652 billion CNY. His best return during his tenure is 183.83%, while the worst is -30.4% [3]

Core Insights - Yinosh experienced a slight decline of 0.31% on August 22, with a trading volume of 55.43 million yuan [1] - The company reported a financing buy-in amount of 10.08 million yuan and a net financing buy of 0.61 million yuan on the same day [1] - As of August 22, the total financing and securities lending balance for Yinosh was 92.67 million yuan, accounting for 7.84% of its market capitalization [1] Financing and Securities Lending - On August 22, Yinosh had a financing buy-in of 10.08 million yuan, with a financing balance of 92.67 million yuan [1] - The company had no securities lending transactions on that day, with a remaining balance of 0.00 shares [1] Company Overview - Shanghai Yinosh Biotechnology Co., Ltd. was established on May 12, 2010, and is located in the China (Shanghai) Pilot Free Trade Zone [1] - The company specializes in providing comprehensive research and development services (CRO) primarily focused on non-clinical research in biomedicine, with 95.42% of its revenue coming from non-clinical services [1] - As of March 31, the number of shareholders was 5,435, a decrease of 46.05%, while the average circulating shares per person increased by 97.22% to 5,187 shares [1] Financial Performance - For the period from January to March 2025, Yinosh reported a revenue of 209 million yuan and a net profit attributable to shareholders of 5.52 million yuan, reflecting a year-on-year decrease of 90.30% [1] - Since its A-share listing, Yinosh has distributed a total of 45.11 million yuan in dividends [2] Institutional Holdings - As of March 31, 2025, the top ten circulating shareholders included notable institutional investors such as Agricultural Bank of China Medical Health Stock and China Europe Medical Health Mixed Fund, with varying increases in their holdings [2]

将投中网设为"星标⭐"，第一时间收获最新推送 并购流行起"差异化对价"。 作者丨蒲凡 编辑丨张楠 来源丨 投中网 最近一年，投资圈越来越流行"并购进入黄金时代"的说法。人们给出的理由主要有两个，一个是目前距离美元大放水时代已经整整过去了4年，创业者们 不再抱有幻想、投资人们没有了耐心，优质资产纷纷回到一个合理的估值区间，是抄底的好窗口；另一个是新"国九条""科创板八条"等一系列政策出 台，赋予了"并购"前所未有的正面定性，买方数量将大大增加。 近日，上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"）宣布将收购澎立生物医药技术（上海）股份有限公司（以下简称"澎立生物"）。交易对 手除了澎立生物实控人JIFENG DUAN控制的实体外，均是澎立生物的外部投资机构。经奥浦迈与交易对方充分协商，澎立生物100%股权的最终交易总 价约为14.51亿元。 这笔交易再一次复现了2023年底，歌尔股份收购驭光科技的操作，即相比最后一轮融资，收购折价近半。根据奥浦迈发布的公告， 澎立生物用2年半时 间完成了估值1460%的倍增，又在3年后出现了55%的折价，过程中"欲IPO而不得"，最终被一家营收规模、净利润都未明显强于自己 ...